30 Day Trial

Anika Therapeutics Reports 2Q19 Orthobiologic Revenue of $26.5MM, +1% vs. 2Q18

Share:

Anika Therapeutics posts 2Q19 orthobiologic revenue of USD $26.5MM, +1% vs. 2Q18.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.